Theriva Biologics (TOVX) Cash & Equivalents (2010 - 2026)

Theriva Biologics (TOVX) has reported Cash & Equivalents for 17 consecutive years, with $14.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 44.11% year-over-year to $14.4 million; the TTM figure through Mar 2026 stood at $14.4 million (up 44.11% YoY), while the FY2025 annual figure was $13.1 million, up 12.46% from the prior year.
• Cash & Equivalents improved to $14.4 million in Q1 2026 per TOVX's latest filing, from $13.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $56.7 million in Q1 2022 and bottomed at $7.5 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $26.2 million across 5 years, with a median of $18.3 million in 2024.
• Annual changes were most pronounced in 2025 — Cash & Equivalents slumped 54.29% — and 2026, when it surged 44.11%.
• Theriva Biologics' Cash & Equivalents stood at $41.8 million in 2022, then slumped by 44.53% to $23.2 million in 2023, then slumped by 49.91% to $11.6 million in 2024, then advanced by 12.46% to $13.1 million in 2025, then gained by 10.53% to $14.4 million in 2026.
• Business Quant data shows TOVX's Cash & Equivalents at $14.4 million in Q1 2026, $13.1 million in Q4 2025, and $7.5 million in Q3 2025.